https://pharmadog.xyz/news/433679 pharmadog en 2026-09-21T04:05:00.000Z Experts see Replimune’s Tudriqev approval as a step toward broader use of localized cancer therapies https://pharmadog.xyz/news/433680 pharmadog en 2026-09-21T04:02:00.000Z FDA’s new CBER and CDER heads back adaptive framework for rare disease therapies https://pharmadog.xyz/news/433681 pharmadog en 2026-09-21T04:00:00.000Z Transposase-based cell line platform speeds development and raises protein yields for complex biologics https://pharmadog.xyz/news/432751 pharmadog en 2026-09-20T23:25:57.000Z Telix to acquire ITM Isotope Technologies in $1.65 billion radiopharma merger https://pharmadog.xyz/news/426059 pharmadog en 2026-09-19T14:13:11.000Z Jehovah's Witnesses ease ban, permitting blood-derived products while still forbidding whole-blood transfusions https://pharmadog.xyz/news/425235 pharmadog en 2026-09-19T10:00:19.000Z Novartis faces another setback while Novo drops Nordisk partnership